Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus - Tabular View

Tracking Information

First Received Date ^ICMJE

January 16, 2001

Last Updated Date

June 23, 2005

Start Date ^ICMJE

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

Complete list of historical versions of study NCT00008749 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus

Official Title ^ICMJE

Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus

Brief Summary

Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.

Detailed Description

Study Phase

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Natural History, Case Control

Condition ^ICMJE

Lupus Erythematosus, Systemic

Intervention ^ICMJE

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Enrollment ^ICMJE

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion:

A diagnosis of systemic lupus erythematosus

Gender

Both

Ages

13 Years and older

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact: Randy Q Cron, MD, Ph.D.

215-590-1844

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00008749

Responsible Party

Study ID Numbers ^ICMJE

NCRR-M01RR00240-1736

Study Sponsor ^ICMJE

National Center for Research Resources (NCRR)

Collaborators ^ICMJE

Arthritis Foundation

Investigators ^ICMJE

Information Provided By

National Center for Research Resources (NCRR)

Verification Date

December 2003

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP